ESMO 2022 | Advances in novel ADCs for HER2-expressing breast cancer

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of recent developments in antibody-drug conjugate (ADC) for HER2-expressing breast cancer. The DESTINY-Breast04 trial (NCT03734029) has shown promising results for trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer. Additional ADCs currently being investigated include disitamab vedotin, trastuzumab duocarmazine, and sacituzumab govitecan. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.